pharma news today obesity drugs glp-1 october 2025 Market Obesity GLP-1 Market
Description
With the participation of researchers from the Paul Langerhans Institute Dresden (PLID), partner at the German Center for Diabetes Research, a GLP-1 receptor agonist in the form of tablets could for the first time be compared with the most common second-line therapy of T2D, a DPP-IV inhibitor
Why are people microdosing weight-loss drugs
Clean, Vegan, and Transparency-Focused: Optiwav 12-in-1 GLP-1 Support is a clean-label vegan supplement made without sugar, gluten, soy, dairy, or artificial additives
Gastrointestinal symptoms such as nausea, constipation, and indigestion are most common and usually subside as your body adjusts
